• My Account
  • Sign In
  • Compare Products
  • Create an Account
Toggle Nav
My Cart
Search
Advanced Search
Menu
Account

Search results for: 'Augmentin-375mg-120-Tablets'

    Select your dosage
    Rx Prescription Required
  1. Ciprofloxacin-750mg-180-Tablets
    Product of India IN Flag
    Rx Prescription Required
    Manufactured by Cipla
    $62.35
  2. Ciprofloxacin-250mg-180-Tablets
    Product of India IN Flag
    Rx Prescription Required
    Manufactured by Cipla
    $59.01
  3. Renvela-800mg-180-Tablets
    Product of India IN Flag
    Rx Prescription Required
    Manufactured by Cipla
    $253.99
  4. Aggrenox-200/25mg-180-Tablets
    Product of India IN Flag
    Rx Prescription Required
    Manufactured by Boehringer ingelhein
    $182.19
  5. Darunavir-300mg-180-Tablets
    Product of India IN Flag
    Rx Prescription Required
    Manufactured by Cipla
    $307.01
  6. Isentress-400mg-180-Tablets
    Product of India IN Flag
    Rx Prescription Required
    Manufactured by Merck Sharp & Dhome
    $1,253.48
Shop By
Now Shopping by
  1. Category RX Products Remove This Item
  2. Quantity Unit 180 Tablet Remove This Item
Clear All
Compare Products
  1. Remove This Item
Compare
Clear All
You have no items to compare.
My Wish List
Last Added Items
  1. Add to Cart
    Remove This Item
Go to Wish List
You have no items in your wish list.

All product names, logos, and brands are the sole property of their respective owners. The products referenced on this website, under the umbrella of Republic Pharma, are not in any way associated or affiliated with our organization. The use of these names, logos, and brands does not imply endorsement. The names are used solely for the purpose of identifying the specific products of respective owners. We hold no claim or ownership over any trademarks, registered or otherwise. Any potential claims or issues related to trademarks should be directed towards their respective owners, as Republic Pharma acts independently and does not infringe upon any trademarks or registered entities. Future content production shall follow similar guidelines of rightful and respectful usage.